Adare Pharma Solutions and Laxxon Medical 3D Printing Collaboration

Adare Pharma Solutions has teamed up with Laxxon Medical to introduce cGMP 3D printing capabilities at Adare’s Pessano facility in Milan, Italy. The partnership utilizes the Screen-Printed Innovative Drug (SPID®) Technology, licensed from Exentis Group, to develop 3D-printed oral dosage forms with advanced geometric structures and customizable release profiles. These innovations allow for the formulation of complex pharmaceuticals with enhanced bioavailability and tailored pharmacokinetics, offering flexibility in dosing, solubility enhancement, and ease of swallowing. The fully operational 3D printing system is set to launch by the end of Q4 2024, with the Pessano site capable of scaling production from lab to clinical volumes.

This collaboration aligns with Adare’s commitment to expanding its end-to-end CDMO services globally, with plans for a second clinical-scale 3D production system at its Vandalia, Ohio facility by the end of 2024. Tom Sellig, CEO of Adare, noted that the Pessano site will serve pharmaceutical customers across Europe, the U.S., and Asia. Laxxon Medical CEO, Helmut Kerschbaumer, emphasized that Adare’s expertise and cutting-edge facilities will accelerate Laxxon’s mission of advancing global drug delivery and manufacturing solutions.